학술논문
Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation.
Document Type
Academic Journal
Author
Thiele Orberg E; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany. e.orberg@tum.de.; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany. e.orberg@tum.de.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany. e.orberg@tum.de.; Meedt E; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany.; Xue J; Institute of Virology, Helmholtz Zentrum Munich, Munich, Germany.; Chair of Prevention for Microbial Infectious Disease, Central Institute of Disease Prevention and School of Life Sciences, Technical University of Munich, Munich, Germany.; Heinrich P; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Leibniz Institute for Immunotherapy, Regensburg, Germany.; Ru J; Institute of Virology, Helmholtz Zentrum Munich, Munich, Germany.; Chair of Prevention for Microbial Infectious Disease, Central Institute of Disease Prevention and School of Life Sciences, Technical University of Munich, Munich, Germany.; Ghimire S; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Miltiadous O; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Lindner S; Department of Immunology, Sloan Kettering Institute, New York, NY, USA.; Tiefgraber M; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Göldel S; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Eismann T; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Schwarz A; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Göttert S; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Jarosch S; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich, Munich, Germany.; Steiger K; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany.; Comparative Experimental Pathology, School of Medicine, Technical University of Munich, Munich, Germany.; Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.; Schulz C; Department of Internal Medicine II, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.; Gigl M; Bavarian Center for Biomolecular Mass Spectrometry, School of Life Sciences, Technical University of Munich, Freising, Germany.; Fischer JC; Department of Radiation Oncology, School of Medicine, Technical University of Munich (TUM), Klinikum rechts der Isar TUM, Munich, Germany.; Janssen KP; Department of Surgery, School of Medicine, Technical University of Munich (TUM), Klinikum rechts der Isar TUM, Munich, Germany.; Quante M; Department of Internal Medicine II, University Medical Center, Freiburg, Germany.; Heidegger S; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.; Herhaus P; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Verbeek M; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; Ruland J; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.; Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany.; van den Brink MRM; Department of Immunology, Sloan Kettering Institute, New York, NY, USA.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.; Weber D; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Edinger M; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Leibniz Institute for Immunotherapy, Regensburg, Germany.; Wolff D; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Busch DH; Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich, Munich, Germany.; German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.; Kleigrewe K; Bavarian Center for Biomolecular Mass Spectrometry, School of Life Sciences, Technical University of Munich, Freising, Germany.; Herr W; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Bassermann F; Department of Internal Medicine III, School of Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.; German Cancer Consortium (DKTK), partner-site Munich, a partnership between DKFZ and Klinikum rechts der Isar, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Munich, Germany.; Gessner A; Institute of Clinical Microbiology and Hygiene, University Medical Center, Regensburg, Germany.; Deng L; Institute of Virology, Helmholtz Zentrum Munich, Munich, Germany.; Chair of Prevention for Microbial Infectious Disease, Central Institute of Disease Prevention and School of Life Sciences, Technical University of Munich, Munich, Germany.; Holler E; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany.; Poeck H; Department of Internal Medicine III, Hematology and Medical Oncology, University Medical Center, Regensburg, Germany. hendrik.poeck@ukr.de.; Leibniz Institute for Immunotherapy, Regensburg, Germany. hendrik.poeck@ukr.de.; Bavarian Cancer Research Center (BZKF), Regensburg, Germany. hendrik.poeck@ukr.de.
Source
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE
Subject
Language
English
Abstract
The microbiome is a predictor of clinical outcome in patients receiving allogeneic hematopoietic stem cell transplantation (allo-SCT). Microbiota-derived metabolites can modulate these outcomes. How bacteria, fungi and viruses contribute to the production of intestinal metabolites is still unclear. We combined amplicon sequencing, viral metagenomics and targeted metabolomics from stool samples of patients receiving allo-SCT (n = 78) and uncovered a microbiome signature of Lachnospiraceae and Oscillospiraceae and their associated bacteriophages, correlating with the production of immunomodulatory metabolites (IMMs). Moreover, we established the IMM risk index (IMM-RI), which was associated with improved survival and reduced relapse. A high abundance of short-chain fatty acid-biosynthesis pathways, specifically butyric acid via butyryl-coenzyme A (CoA):acetate CoA-transferase (BCoAT, which catalyzes EC 2.8.3.8) was detected in IMM-RI low-risk patients, and virome genome assembly identified two bacteriophages encoding BCoAT as an auxiliary metabolic gene. In conclusion, our study identifies a microbiome signature associated with protective IMMs and provides a rationale for considering metabolite-producing consortia and metabolite formulations as microbiome-based therapies.
(© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
(© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)